U.S. markets closed

10x Genomics, Inc. (TXG)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
193.51+2.35 (+1.23%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close191.16
Open192.93
Bid193.49 x 1300
Ask197.47 x 1000
Day's Range190.30 - 194.76
52 Week Range80.90 - 203.25
Volume636,761
Avg. Volume821,865
Market Cap21.247B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-5.41
Earnings DateAug 04, 2021 - Aug 09, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est205.71
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 10x Genomics Unlocks Whole Transcriptome Analysis in FFPE Tissues With New Visium Assay, Now Shipping
    GlobeNewswire

    10x Genomics Unlocks Whole Transcriptome Analysis in FFPE Tissues With New Visium Assay, Now Shipping

    Fueling Discovery in Preserved Tissue Samples to Advance Clinical Translational ResearchPLEASANTON, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today announced it is shipping its new Visium Spatial Gene Expression for FFPE (formalin-fixed and paraffin-embedded) assay. The offering gives researchers access to the whole transcriptome across their entire tissue, enabling true unbiased discovery in FFPE samples for the first time. The product addresses customer demand

  • Motley Fool

    Here's Why 10x Genomics Can't Satisfy Short-Term Investors

    10x Genomics (NASDAQ: TXG), which is focused on helping researchers study genomic changes on a cellular level, beat Wall Street expectations in the first quarter, but shares of the company fell substantially. In this video from Motley Fool Live, recorded on May 10, Fool.com contributors Brian Orelli and Keith Speights discuss why the share price dropped and why the short-term move shouldn't affect long-term investors. Brian Orelli: Not every company had an impressive first quarter.

  • 10x Genomics Stock Shows Rising Price Performance With Jump To 83 RS Rating
    Investor's Business Daily

    10x Genomics Stock Shows Rising Price Performance With Jump To 83 RS Rating

    10x Genomics Inc Cl A shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.